Brief: Chemomab Therapeutics Announces Fourth Quarter And Year End 2021 Financial Results And Provides A Corporate Update

Chemomab Therapeutics

09/03/2022 11:04

March 9 (Reuters) - Chemomab Therapeutics Ltd  CMMB.O :
    * CHEMOMAB THERAPEUTICS ANNOUNCES FOURTH QUARTER AND YEAR
END 2021
FINANCIAL RESULTS AND PROVIDES A CORPORATE UPDATE
    * Q4 LOSS PER SHARE $0.02
    * MAKING REVISIONS TO ITS CURRENT CLINICAL PROGRAMS
    * CHEMOMAB THERAPEUTICS - PLANS TO IMPLEMENT A DOSE FINDING
COMPONENT TO CM-101 DEVELOPMENT PROGRAM BY SIGNIFICANTLY
EXPANDING ITS PHASE 2 TRIAL FOR PSC
    * WILL BE INCREASING SIZE OF PHASE 2 TRIAL FOR PSC BY ADDING
ADDITIONAL DOSE COHORTS
    * CHEMOMAB THERAPEUTICS - PLANS TO FOCUS ITS SSC TRIAL
TOWARDS
ESTABLISHING BIOLOGICAL AND CLINICAL PROOF OF CONCEPT IN THIS
PATIENT POPULATION
    * CHEMOMAB THERAPEUTICS - WINDING DOWN ENROLLMENT IN SAFETY,
PHARMACOKINETIC & BIOMARKER LIVER FIBROSIS STUDY, YIELDING DATA
READOUT TARGETED NEAR END OF 2022
    * QTRLY BASIC AND DILUTED LOSS PER ORDINARY SHARE $0.022

Source text for Eikon:  ID:nPn6yNsr1a 
Further company coverage:  CMMB.O